消癌平注射液联合表柔比星新辅助化疗治疗三阴性乳腺癌的临床疗效

摘要

Objective To explore the clinical efficacy of Xiao'aiping injection combined with neo-adjuvant chemotherapy with epiru-bicin in the treatment of triple negative breast cancer. Methods Eighty patients diagnosed with triple-negative breast cancer in our hospital were selected and divided into two groups by random number table. The patients in the control group were treated with epirubicin alone. And those in observation group were treated with Xiao'aiping injection and epirubicin. The clinical efficacy, levels of IL-6, IL-8, TNF-α, quality of life, and adverse reactions before and after treatment were compared between the two groups. Results The clinical efficacy of the observation group was significantly better than that of the control group (P0.05). After treatment, the levels of IL -6 and IL-8 were significantly lower in observation group than in control group (P0.05). However, after treatment, the scores of the above mentioned were significantly higher in observation group than in con-trol group (P0.05),治疗后观察组明显优于对照组(P0.05),治疗后观察组上述评分均显著高于对照组(P<0.05);观察组患者不良反应发生率明显低于对照组(P<0.05).结论 消癌平注射液联合表柔比星新辅助化疗治疗三阴性乳腺癌的效果显著,值得临床推广应用.